20 High-Quality Stocks to 'Fall' Back On
Given the uncertainty so characteristic of autumn, consider hunkering down with the stocks in our current Wide Moat Focus Index.
Given the uncertainty so characteristic of autumn, consider hunkering down with the stocks in our current Wide Moat Focus Index.
Autumn is upon us, and let's hope the harvest moon shines as brightly as the market did over the summer. Recent returns to U.S. equity investors went a long way toward making up for the cold shoulder we got in 2008.
Once again, returns were even better for the portfolio of stocks that comprise our Morningstar Wide Moat Focus. This index is composed of the cheapest wide-moat firms in our 1,800-stock coverage universe. Index constituents are firms with the strongest competitive advantages in their industries and the ones where we believe the advantages will persist many years into the future.
Only 175 companies that we cover (fewer than 10%) bear our wide economic moat rating. For inclusion in this index, we pick the 20 cheapest (based on stock price/fair value) wide-moat firms every three months, and we readjust the holdings to equal-weight them at 5% of the portfolio apiece. These are not necessarily 5-star-rated picks, but the cheapest wide-moat stocks we have to offer. The result is a fresh collection of high-quality firms with undervalued stocks.
The previous index, before its reconstitution, ran from June 22 until Sept. 18 and racked up a 22.4% return over that period, compared with the S&P 500's total return of 16.6%. As of Sept. 19, the index had increased 41.6% year to date and had a 6.0% annualized return over a three-year period. These longer-term returns are also significantly outperforming the market.
While nearly every stock in the previous portfolio increased in value from June to September, four had returns in excess of 40%. Harley-Davidson (HOG) (52% return), American Express (AXP) (44%), KLA-Tencor (KLAC) (42%), and Time Warner Cable (42%) were the standouts. Harley-Davidson and Time Warner Cable were added to the index only at its prior rebalancing in June, and Harley-Davidson is no longer a constituent as its runup made it ineligible for the current portfolio. It's always nice to have big winners right away. American Express has continued its hot streak, having also increased 104% in the March-to-June index, yet it remains in the current portfolio at a price/fair value of 63%. We still believe Amex has plenty of upside. The only stock in the previous portfolio not to post a positive total return was Eli Lilly (LLY), which lost 1% in the period.
Autumn has historically been a difficult time for the broader stock market, and this year many investors are especially anxious due to the market's run since March. Despite the uncertainty, we remain confident that over the long term strong firms will continue to outperform both weaker firms and the broader market. We believe that our "buy great firms with significantly undervalued stocks" strategy will persevere despite the vicissitudes of the market, even though past performance cannot predict future returns. Given the uncertainty so characteristic of autumn, you may want to consider hunkering down with the stocks in our current index.
Current Constituents of Morningstar Wide Moat Focus Index*
* Data as of Sept. 24, 2009
The current portfolio contains six newcomers--firms that weren't cheap enough to include in the prior portfolio but are cheap enough for us now. The most undervalued of the six is Boston Scientific (BSX), trading at 59% of its fair value estimate as of Sept. 24. Senior analyst Debbie Wang believes Boston Scientific struggled with a large case of indigestion after its pricey Guidant acquisition and a stent market slowdown. However, the stent and cardiac rhythm management markets have now stabilized, and even with her conservative expectations for near-term performance she believes this stock is undervalued. It's one to keep an eye on, for sure.
Monsanto is the penultimate undervalued new addition, trading at 63% of our fair value estimate. Senior analyst Ben Johnson likes this seed producer. "Monsanto is a fierce competitor that continues to dominate a market that it essentially created more than a decade ago. Through its ongoing commitment to research and development and assertive capital allocation, the company has positioned itself to grow value for its shareholders over the long haul." You may want to consider planting this stock in your portfolio.
Rounding out our group of newcomers are Weight Watchers (WTW), Exelon (EXC), General Electric (GE), and Apollo Group . Click through to the companies' Analyst Reports or visit our Web site to see for yourself why our analysts are bullish on these undervalued, wide-moat stocks.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.